# **NEW YORK STATE**

**MEDICAID PROGRAM** 

**LABORATORY** 

**PROCEDURE CODES** 

# **Table of Contents**

GENERAL INFORMATION AND RULES	3
ORGAN OR DISEASE ORIENTED PANELS	12
DRUG TESTING	13
THERAPEUTIC DRUG ASSAYS	13
EVOCATIVE/SUPPRESSION TESTING	14
URINALYSIS	14
MOLECULAR PATHOLOGY	15
MULTIANALYTE ASSAYS WITH ALGORITHMIC ANALYSES	19
CHEMISTRY	19
HEMATOLOGY AND COAGULATION	26
IMMUNOLOGY	28
TRANSFUSION MEDICINE	31
MICROBIOLOGY	32
CYTOPATHOLOGY	36
CYTOGENETIC STUDIES	37
SURGICAL PATHOLOGY	38
OTHER PROCEDURES	40

## **GENERAL INFORMATION AND RULES**

- 1. The fees in the Laboratory Fee Schedule apply to clinical laboratory tests selected from <a href="Physician's Current Procedural Terminology">Physician's Current Procedural Terminology</a> (CPT), Fourth Edition, 2005 revision or the <a href="Healthcare Common Procedure Coding System">Healthcare Common Procedure Coding System</a> (HCPCS), Seventeenth Edition, 2005. Reimbursement is limited to indicated uses of procedures that are FDA approved for in vitro diagnostic use or, are recognized as generally acceptable by the New York State Department of Health.
- 2. The fees include the services of all licensed professionals required by certification in the performance of the test.
- 3. The fees include all costs related to specimen testing, including collection, storage and transport of specimens, in addition to performance and reporting of results. Unreported instrument controls are not separately reimbursable. "By Report" (BR), as indicated in the Fee Schedule, reimbursement requires a statement indicating the need for the service, the type of test performed, the number and source of the specimen(s) and documentation, of the laboratory's usual and customary charge to the general public for the service.
- 4. The fees are for **quantitative** analyses, unless otherwise specified. Mathematical calculations (e.g., calculation of A/G ratio, ionized calcium, free thyroxine index (T-7) or osmolality) are not reimbursable.
- 5A. Therapeutic drug monitoring is reimbursable when quantitative determination of blood concentration is clinically relevant as a part of a regimen designed to attain and sustain therapeutic effect by maintenance of blood level within a defined range. The intensity and probability of therapeutic or toxic effect must quantitatively correlate with blood concentration. In addition, one or more of the following criteria must be satisfied: (1) there is a narrow range between those concentrations giving the desired response and those producing toxicity, (2) readily assessed alternative endpoints(e.g., prothrombin time for oral anticoagulants) are lacking or (3) there is large interindividual variability in the absorption and disposition of the drug.

Therapeutic monitoring is a covered service only when performed on specimens of **blood**. Use the drug specific codes 80150-80202, 82980 or 83858. Codes 80299 or 82205 are to be used only for drugs, which meet the criteria for therapeutic monitoring, outlined above and are not listed by individual code. Codes 80299 and 82205 are billable "**By Report**" and the drug(s) must be specified in the procedure description field on the Claim Form.

Peak and trough (or predose and postdose) analyses, when clinically indicated (e.g., aminoglycosides), are reimbursable as two procedures.

- 5B. The fee for code 80100, 80101 or 80104 covers screening of one specimen for any drugs including but not limited to alcohol, amphetamines, barbiturates, benzodiazepines, cocaine and metabolites, methadone, methagualones, opiates, phencyclidines, phenothiazine, propoxyphenes, quinine, tetrahydrocannaboinoids (marijuana) and tricyclic antidepressants. Screening by a broad-spectrum chromatographic procedure, which detects multiple drug classes, should be billed using code 80100. Each step in the sequential development of a chromatograph is NOT considered a separate procedure. When an analytical condition, e.g., column temperature or flow rate, is changed such that additional controls must be run, subsequent analysis of the same specimen for additional drug(s) is considered a separate procedure for billing purposes. Screening for multiple classes of drugs, other than broad spectrum chromatographic procedures, in a single test procedure should be billed using code 80104. Screening by immunoassay or a chromatographic method, which detects a single drug or drug class should be billed, per procedure, using code 80101. Confirmation of presumptive positives (or presumptive negatives for compliance monitoring) MUST be by methodology of differing chemical and physical principle from that used in the initial screen. Code 80102 is billable per confirmatory procedure, regardless of analytical method. Quantitation of detected drugs is not reimbursable. Code 82205 is for therapeutic monitoring only.
- 6A. Certain laboratory procedures are often performed, either manually or on automated equipment, in combination with each other. For purposes of reimbursement, when a code defines a specific combination of procedures performed on a date of service, it is appropriate to utilize that unique code.
- 6B. When procedures for Vitamin B12 (82607) and Folate (82746 or 82747) are performed in combination, the maximum reimbursable fee for code 82746 or 82747 is \$6.25. When a procedure for Ferritin (82728) is performed in combination with Vitamin B12 or Folate, or any of the Organ or Disease Oriented Panels (80048-80076), or any of the individual chemistry analyte codes listed in the fee schedule (see Rule 6A), the maximum reimbursable fee for 82728 is \$5.70.
- 6C. When two or more Hepatitis B tests are performed in combination, reimbursement will be reduced by 50% for each test after the first. See also Rule 16. When Hepatitis A, C or D tests (codes 86692, 86708, 86709, 86803 or 87380) are performed in combination with each other or with any Hepatitis B test, the maximum reimbursable fee per Hepatitis A, C or D test is \$5.00. When multiple procedures for antigen or antibody to two or more infectious agents (codes 86602-86689 and 86698-86703 or 86710-86793) are performed in combination, reimbursement is limited to the greater fee plus 50% of the lesser fee(s). The fee for code 86701 Antibody HIV-1 includes reimbursement for up to three screen assays of a single specimen. Use code 87390 for P24 HIV antigen.
- 7A. For purposes of reimbursement based on the Laboratory Fee Schedule, a complete blood count (CBC) includes a hematocrit, hemoglobin determination, RBC count, RBC indices, WBC count and a platelet count. See code 85027. For a CBC with an automated differential WBC count, use code 85025. Code 85060 requires interpretation by physician and written report.

- 7B. Codes for CBC individual components (85013, 85014, 85018, 85048 and 85049) may not be billed in conjunction with procedure codes including a CBC (85025 and 85027). The code for automated differential WBC count (85004) may not be billed in conjunction with codes 85025 and 85027.
- 8. For purposes of reimbursement, codes 86850-86905 represent examples of procedures considered to be integral parts of outpatient transfusion and hemodialysis services. No separate reimbursement will be allowed.
- 9. For pregnancy detection and where the reported test result is qualitative or semi-quantitative, use code 81025 or 84703. Code 84702 is reimbursable for a quantitative HCG value reported for a diagnostic use (e.g., monitoring post surgical growth of germ cell neoplasm where quantitative HCG is relative to growth). Code 84702 is not reimbursable for a routine screen for pregnancy.
- 10. Appropriate billing of antibody and antigen procedures is as follows:
  - A. For antibody or antigen as specific markers of infectious disease, use the most specific code corresponding to the organism name (e.g., 86618 Antibody; Borrelia burgdorferi) or the disease name (e.g., 87340 Hepatitis B surface antigen).
  - B. For an infectious agent antibody or antigen not listed by name, use the "By Report" code for the type of organism (e.g., 86609 Antibody; bacterium not elsewhere specified or the analytical method, e.g. 87299 Infectious agent antigen detection by immunofluorescent technique; not otherwise specified, each organism). Document the name of the organism, and, if applicable, the immunoglobulin subclass(es), on the Claim Form (See Rule 3).
  - C. For antibody other than to infectious agent(s) (e.g., autoantibodies) use the most specific code corresponding to the analyte (e.g., 86376 Microsomal antibody (e.g. thyroid or liver-kidney, each)).
  - D. For non-infectious agent antibody or antigen NOT listed by analyte, use the most specific code for the method used (e.g., 86255 Fluorescent noninfectious agent antibody; screen each antibody); when billing "By Report", the name of the analyte must be documented on the Claim Form (See Rule 3).
  - E. Multiple tests to detect (1) antibodies to organisms/analytes classified more precisely than the specificity allowed by available codes, (2) antibodies in paired specimens (acute vs. convalescent), or (3) antibodies of different immunoglobulin subclasses, are reimbursable as separate procedures; multiple units of a code (e.g., two units of 86658 for Coxsackie A and B species of enterovirus) may be claimed when analyses yield separately reported results for each subclassification, specimen or Ig subclass.

- 11. Organ or Disease Orientated Panel codes. Effective July 1, 2000, the panel codes 80047, 80048, 80051, 80053, 80061, 80069 and 80076 should be used to bill designated combinations of tests regardless of whether the tests are ordered and/or performed individually, as a panel, or as multiple panels at different times. If 2 or more panel codes with overlapping component tests, (i.e., 80047, 80048, 80051, 80053, 80076) are billed, the lab is not entitled to reimbursement for the duplicate tests. If one or more of the codes for chemistry tests where this rule applies are billed in combination with another and/or a panel code, total payment due for those chemistry tests is limited as follows: up to 2=\$5.03, 3-6=\$6.04, 7-9=\$7.25, 10-12=\$9.09, 13-16=\$10.00, 17-18=\$11.00, 19 or more=\$12.00.
- 12. Cytogenetic studies codes 88245, 88267 and 88269 must be billed in combination with code 88280 to report a 2-karyotype chromosome analysis as described in the quality control standards for cytogenetic licensure.
- 13. Reimbursement for immunoelectrophoresis includes payment for the electrophoretic separation and quantitation. Therefore, no separate reimbursement for code 84165 will be allowed when code(s) 86320-86325 are billed.
- 14. The molecular pathology codes (81400-81408) are reimbursable for **DNA-based** genetic testing not specifically listed in the fee schedule and performed as (1) a family study of up to six individuals to determine the genetic carrier/disease status of an individual patient or a fetus as part of a comprehensive program of genetic counseling and where indicated by familial medical history or adjunctive prenatal testing **OR** (2) an individual study by diagnostic deletion analysis of a patient affected by a genetic disorder. DNA-based testing defined under State licensure as investigational for a certain disease is not reimbursable. Codes 81400-81408 are not reimbursable for non-genetic applications such as microbial detection or quantification, or testing for acquired changes in genetic material (e.g., T or B cell markers, immunoglobulin heavy or light chain rearrangements associated with malignancy). Reimbursement for these codes should be submitted according to the "By Report" instructions in Rule 3.
- 15. Code 82105, 82106, 82378, 83950, 83951, 84066, 84153, 84154, 84702 or 86316 is reimbursable for an **oncofetal antigen** (tumor marker) procedure used as an adjunctive test with other accepted tests in monitoring for tumor growth recurrence in a patient who has had a tumor irradiated or surgically removed. Codes 82105 and 82106 are also reimbursable for alpha-fetoprotein testing used for prenatal (nondiagnostic) gestational age dependent screening for neural tube defects. Code 86316 for immunoassay for a tumor antigen not elsewhere specified, e.g., CA 50, is billable "**By Report**". When a procedure for (CEA) carcinoembryonic antigen (82378) is performed in combination with Comprehensive Metabolic Panel (code 80053) the maximum reimbursable fee for code 82378 is \$8.00. A test for an oncofetal antigen (tumor marker) is reimbursable for diagnostic purposes only when used in accordance with the FDA approval criteria for its use. When 84153 and 84152 or 84154 are billed in combination, the maximum fee for 84152 or 84154 is \$21.35.
- 16. Claims for reimbursement for procedures generally considered to be follow-up testing

must be supported by reporting a specific (presumptive) diagnosis which considers the results of the initial test(s) as well as the patient's history, symptoms, etc. The ordering practitioner must supply such diagnosis, or reason for the patient encounter, to the laboratory. For example:

- A. Code 82172 is reimbursable when performed for diagnostic purposes for a patient with documented elevated total cholesterol (>240 mg/dl) and an abnormally low HDL cholesterol level (< 35 mg/dl) and/or documented family history of coronary artery disease (CAD). A test for apolipoprotein(s) is **not** reimbursable when used as a **screening** procedure for CAD risk assessment.
- B. Thyroid function tests other than "screen" tests for clinically suspected thyroid dysfunctions are reimbursable only when indicated for differential diagnosis, to resolve disagreement with documented clinical impressions, to resolve equivocal results or to monitor therapeutic regimens of diagnosed thyroid-dysfunctional patients. For purposes of this rule, a "screen" test is either total thyroxine (84436) or free thyroxine index (84436 + 84479) or sensitive-TSH (84443).
- C. Serologic markers that are clinically indicated for staging, management or prognosis of viral hepatitis B are reimbursable only when it is determined by initial diagnostic testing that the patient has type B hepatitis.
- 17. The fee for presumptive identification of microbial culture isolates includes reimbursement for all procedures used to presumptively identify the organism, including stains. When definitive identification is medically necessary and additional methods are used for definitive identification, (e.g., molecular methods) use code 87076 or 87077, as applicable, in addition to the appropriate code for isolation (87040 87075).
- 18. Lymphocyte evaluation by immunophenotyping is reimbursable for analysis of lymphocyte subpopulations for monitoring of disease activity and therapeutic response in, for example, immunodeficiency or autoimmune disease, or cancer. Only those antibodies or "markers" FDA-approved or cleared and/or approved by the Department are reimbursable as follows:
  - A. Bill 1 unit of code 86360 when the lab performs an "abbreviated lymphocyte" analysis panel\* by 2-color flow cytometric analysis or any acceptable tube combination out of the possible four analysis tubes by 3 or 4-color flow cytometric analysis, and reports absolute CD4 counts with CD8 counts;
  - B. Bill 2 units of code 86360 when the lab performs a "full lymphocyte" analysis panel\* by 2, 3 or 4-color flow cytometric analysis and reports absolute CD4 counts with CD8 counts. Codes 86355, 86357, 86359, 88184, 88185 and 88187 through 88189 are not reimbursable for a 'full lymphocyte' analysis panel when only performing absolute CD4 counts with CD8 counts;

- C. Bill 1 unit of code 86361 when the lab performs lymphocyte subpopulation counts by a method other than flow cytometry or microscopy, and reports only absolute CD4 counts with or without CD8 counts:
- D. Bill 1 unit of one or more of the codes 86355, 86357, 86359, 86367, 88184 and whenever appropriate, 1 or more units of 88185, when the lab performs flow cytometric testing using multiple markers (e.g. lymphoma/leukemia testing). When CD4/CD8 analysis is included, 1 unit of 86360 should be billed in addition, and when CD4 analysis is included (without CD8), bill 1 unit of 86361 in addition. Codes 86360 and 86361 may not be billed for the same date of service. 88184 and 88185 should be used for unlisted markers, including markers used to draw gates, set cursors and monitor variability. Bill 1 unit of the appropriate interpretation code (88187 through 88189) based on the total number of markers performed;
- E. Bill code 88346 or 88347 when the lab performs microscopic or other non-flow cytometric subset analysis using tagged antibody (ies); bill 1 unit of code 88346 or 88347 per marker.
  - \* "Abbreviated lymphocyte" and "full lymphocyte" panels are as defined by the New York State Cellular Immunology Proficiency Testing Program.
- 19. Code 86341 Islet cell antibody is reimbursable when used to differentiate type I from type II diabetes in patients with equivocal clinical presentation. It is not reimbursable when used as a predicator of disease, e.g., in first-degree relatives of persons with diabetes mellitus.
- 20. Code **87536 HIV-1 quantitation** is reimbursable when used in patient management to predict clinical outcomes, to predict risk of disease progression, and/or to provide information for a decision to initiate antiretroviral drug therapy or to change treatment regimes. This test is allowed as clinically indicated up to a <u>maximum</u> of six per year.
- 21. HIV genotypic/phenotypic drug resistance testing and phenotypic prediction using genotypic comparison to known databases is a covered service when clinically indicated. Medicaid will reimburse each test (87900, 87901, 87903, 87904, 87906) up to a maximum of three times in a 365-day period across all providers. For dates of service on or after January 1, 2010, Medicaid will reimburse for any combination of 87901 and 87903 up to a maximum of four times in a 365-day period across all providers.

Effective for dates of service on and after **April 1, 2002**, code 87903 reimburses \$675.29 for resistance determinations of up to 10 antiviral drugs. Code 87904 should be billed in addition to 87903 to claim reimbursement for additional drug resistance determinations, using one unit for **each (1) additional drug**.

When codes 87901, 87903 and 87906 are billed in combination with the same date of service, the maximum reimbursable fee for any combination of 87901, 87903 and 87906 is \$100 less than the additive maximum fees for the codes.

- 22. For instrumented screening of PAP smears (codes 88174 and 88175), the following definitions apply:
  - A. For code 88174, "screening by automated system" means primary examination by a slide profiling system without human review and primary examination by human review of all fields of vision selected by a locations-guidance system, with or without quality assurance manual or automated re-screening.
  - B. For code 88175, "screening by automated systems and manual rescreening" means primary examination by human review of all or some fields of vision selected by a location guidance system, and, in addition, full slide review (e.g., AutoScan mode engaged), with or without quality assurance manual or automated rescreening.
- 23. Effective September 1, 2004, travel expenses associated with in-home phlebotomy services, i.e., blood draws, is reimbursable using code P9604. The recipient must be eligible for in-home phlebotomy as documented by a qualified ordering practitioner and defined below.

### A recipient is eligible for in-home phlebotomy if:

- The recipient is homebound, which means he or she has a condition due to illness or injury that precludes access to routine medical services outside of his/her residence without special arrangements for transportation, i.e., ambulance, ambulette, and taxi with assistance in areas where public transportation is unavailable; or has a condition that makes leaving the residence medically contraindicated; and,
- The recipient is participating in a Medicaid-covered home care program or is currently receiving a Medicaid-covered home care service, i.e., personal care services, certified home health agency (CHHA) services, consumer-directed personal assistance services, or the Long Term Home Health Care Program (LTHHCP).

### Travel expenses are NOT a covered service if they are solely to:

- 1. Draw blood from patients in a skilled nursing facility;
- Draw blood from a recipient who receives medical services in his or her residence from a professional whose scope of practice authorizes the drawing of blood; or,
- 3. Pick-up and transport a specimen collected by a home health care provider or anyone other than a laboratory representative.

The laboratory is entitled to only one fee for one-way or round-trip travel to a single address, regardless of the number of specimens collected or the number of recipients drawn at that location. There is a limit of 12 claims per recipient per year for in-home phlebotomy service; this allows for 12 round-trips or 12 one-way trips, or any combination of no more than 12 round or one-way trips. The number of specimens collected per trip must be documented.

continued on next page

To calculate the appropriate reimbursement amount for claiming travel to and from in-home phlebotomy services, multiply the number of trips or stops (including the return trip to the laboratory) by the fee and divide this amount by the number of patients seen. The laboratory will pro-rate when the claim is submitted based on the number of patients seen on that trip. The "same address" is defined as a building or complex with the same entrance and egress off of a public road, such as an apartment complex.

### Rules for billing, including pro-rating for multiple recipients:

- **1. One recipient at one site:** A laboratory representative travels from the laboratory to the home of one recipient and returns to the laboratory without making any other stops. The trip out and back is paid as a round-trip. The laboratory should submit a single line claim for \$18.70 (2 x \$9.35 = \$18.70).
- **2.** One recipient at each of multiple sites: A laboratory representative travels in a circuit from the laboratory to the home of each of six recipients and returns to the laboratory. Each segment is paid as a one-way trip at a flat rate of \$9.35. The laboratory is entitled to a total of 65.45 (7 x 9.35 = 65.45) but, since a separate claim must be submitted for each recipient, 65.45 must be divided by the number of recipients, which is six. Each of the six recipient claims would be submitted for \$10.91.
- **3. Multiple recipients at a single address:** A laboratory representative travels from the laboratory to an apartment complex, draws blood from six recipients and returns to the laboratory. The laboratory is entitled to one round trip fee of \$18.70, but, since a separate claim must be submitted for each recipient, the \$18.70 must be divided by the number of recipients, which is six. Each of the six recipients' claims would be submitted for **\$3.12.**
- **4. Multiple recipients at one address + one recipient at each of several additional sites:** A laboratory representative travels from the laboratory to an apartment complex and draws blood from three recipients; he then continues his circuit to three separate residences, and draws blood from one recipient at each, and returns to the laboratory. The laboratory should bill as follows:

The laboratory is entitled to \$9.35 for the trip segment from the laboratory to the apartment complex;

For each of the three recipients drawn at separate addresses, the laboratory is entitled to \$9.35 trip segment. The laboratory is also entitled to \$9.35 for the return to the laboratory. The total would be four times \$9.35, or \$37.40.

The total number of stops are 5 (one stop from the laboratory to the apartment complex, stops at three recipients' homes and the return trip to the laboratory). The laboratory is entitled to a total of 46.75 (5 x 9.35 = 46.75), but since a separate claim must be submitted for each recipient, 46.75 must be divided by the number of recipients which is six. Each of the six recipient's claims would be submitted for 7.79.

24. The Medicaid definition for "date of service" for laboratory providers is the date of specimen collection. For laboratory tests that use a specimen taken from storage, the date of service is the date the specimen was removed from storage.

## 25. NCCI Modifiers:

**Note-** NCCI associated modifiers are recognized for NCCI code pairs/related edits. For additional information please refer to the CMS website: http://www.cms.hhs.gov/NationalCorrectCodInitEd/

- -59 Distinct procedural service
- -91 Repeat clinical diagnostic laboratory test

### **DESCRIPTION**

## **ORGAN OR DISEASE ORIENTED PANELS** (see Rule 11)

80047 Basic metabolic panel (Calcium, ionized)

This panel must include the following:

Calcium, ionized (82330), Carbon dioxide (82374), Chloride (82435), Creatinine (82565), Glucose (82947), Potassium (84132), Sodium (84295), Urea Nitrogen (BUN) (84520)

80048 Basic metabolic panel (Calcium, total)

This panel must include the following:

Calcium, total (82310), Carbon dioxide (82374), Chloride (82435), Creatinine (82565), Glucose (82947), Potassium (84132), Sodium (84295), Urea Nitrogen (BUN) (84520)

80051 Electrolyte panel

This panel must include the following:

Carbon dioxide (82374), Chloride (82435), Potassium (84132), Sodium (84295)

80053 Comprehensive metabolic panel

This panel must include the following:

Albumin (82040), Bilirubin, total (82247), Calcium, total (82310), Carbon dioxide (bicarbonate) (82374), Chloride (82435), Creatinine (82565), Glucose (82947), Phosphatase, alkaline (84075), Potassium (84132), Protein, total (84155), Sodium (84295), Transferase, alanine amino (ALT) (SGPT) (84460), Transferase, aspartate amino (AST) (SGOT) (84450), Urea Nitrogen (BUN) (84520)

80061 Lipid panel

This panel must include the following:

Cholesterol, serum, total (82465), Lipoprotein, direct measurement, high density cholesterol (HDL cholesterol) (83718), Triglycerides (84478)

80069 Renal function panel

This panel must include the following:

Albumin (82040), Calcium, total (82310), Carbon dioxide (bicarbonate) (82374), Chloride (82435), Creatinine (82565), Glucose (82947), Phosphorus, inorganic (phosphate) (84100), Potassium (84132), Sodium (84295), Urea nitrogen (BUN) (84520)

80076 Hepatic function panel

This panel must include the following:

Albumin (82040), Bilirubin, total (82247), Bilirubin, direct (82248), Phosphatase, alkaline (84075), Protein, total (84155), Transferase, alanine amino (ALT) (SGPT) (84460), Transferase, aspartate amino (AST) (SGOT) (84450)

### **DESCRIPTION**

### **DRUG TESTING**

Qualitative screening tests are reimbursable per procedure, not method or analyte, using code 80100 or 80101. Use code 80102 for each procedure necessary for confirmation. See Rule 5B.

Bo100 Drug screen, qualitative; multiple drug classes chromatographic method, each procedure
 80101 single drug class method (e.g., immunoassay, enzyme assay), each drug class
 80102 Drug confirmation, each procedure
 80104 Drug screen, qualitative; multiple drug classes other than chromatographic method, each procedure

### THERAPEUTIC DRUG ASSAYS

Quantitative therapeutic drug monitoring is reimbursable only when performed on specimens of **blood** as outlined in Rule 5A.

(For barbiturates not specifically listed by name, use 82205)

```
80150 Amikacin
80152 Amitriptyline
80156 Carbamazepine; total
80157
           free
80158 Cyclosporine
80160 Desipramine
80162 Digoxin
80164 Dipropylacetic acid (valproic acid)
80166 Doxepin
80168 Ethosuximide
80170 Gentamicin
80173 Haloperidol
80174 Imipramine
80178 Lithium
80182 Nortriptyline
80184 Phenobarbital
80185 Phenytoin; total
80186
           free
80188 Primidone
      Quinidine
80194
80195 Sirolimus
80196 Salicylate
80197
       Tacrolimus
80198 Theophylline
80200
      Tobramycin
80202 Vancomycin
80299 Quantitation of drug, not elsewhere specified (see Rule 5A)
```

**DESCRIPTION** 

## **EVOCATIVE/SUPPRESSION TESTING**

The following tests involve the administration of evocative or suppressive agents and the baseline and subsequent measurement of their effects on chemical constituents. The costs of the evocative or suppressive agents are not included in the fee, with the exception of oral glucose for codes 80430 and 82950 – 82953. Reference to a particular analyte in the code description (e.g., cortisol x 2) indicates the minimum number of times that particular analysis must be performed in order to claim reimbursement for the test. When multiple evocative or suppressive tests are performed in combination reimbursement is limited to the greater fee plus 50% of the lesser fee(s).

80400 80402 80406	ACTH stimulation panel; for adrenal insufficiency (cortisol x 2) for 21 hydroxylase deficiency (cortisol x 2 and 17 hydroxyprogesterone x 2) for 3 beta-hydroxydehydrogenase deficiency (cortisol x 2 and 17 hydroxypregnenolone x 2)
80410	Calcitonin stimulation panel (e.g., calcium, pentagastrin) (calcitonin x 3)
80414	Chorionic gonadotropin stimulation panel; testosterone response (testosterone x 2)
80415	estradiol response (estradiol x 2)
80416	Renal vein renin stimulation panel (e.g., captopril) (renin x 6)
80420	Dexamethasone suppression panel, 48 hour (free cortisol/urine x 2 and cortisol x 2)
80426	Gonadotropin releasing hormone stimulation panel (follicle stimulating hormone (FSH) x 4 and luteinizing hormone (LH) x 4)
80428	Growth hormone stimulation panel (e.g., arginine infusion, I-dopa administration) (human growth hormone (HGH) x 4)
80430	Growth hormone suppression panel (includes glucose) (glucose x 3 and human growth hormone (HGH) x 4)
80432	Insulin-induced C-peptide suppression panel (insulin x 1 and C-peptide x 5 and glucose x 5)
80436 80438	Metyrapone panel (cortisol x 2 and 11-deoxycortisol x 2) Thyrotropin releasing hormone (TRH) stimulation panel; one hour (thyroid stimulating hormone (TSH) x 3)

## **URINALYSIS**

81000	Urinalysis, by dip stick or tablet reagent for bilirubin, glucose, hemoglobin,
	ketones, leukocytes, nitrite, ph, protein, specific gravity, urobilinogen, any
	number of these constituents; non-automated, with microscopy
81001	automated, with microscopy
81002	non-automated, without microscopy
81003	automated, without microscopy
81007	Urinalysis; bacteriuria screen, except by culture or dipstick
81015	microscopic only
81025	Urine pregnancy test, by visual color comparison methods

### **DESCRIPTION**

## MOLECULAR PATHOLOGY

- 81200 ASPA (aspartoacylase) (EG, canavan disease) gene analysis, common variants (eg,e285a, y231x)
- 81201 APC (adenomatous polyposis coli) (eg, familial adenomatosis polyposis [fap], attenuated fap) gene analysis; full gene sequence
- 81202 APC (adenomatous polyposis coli) (eg, familial adenomatosis polyposis [fap], attenuated fap) gene analysis; known familial variants
- 81203 APC (adenomatous polyposis coli) (eg, familial adenomatosis polyposis [fap], attenuated fap) gene analysis; duplication/deletion variants
- 81205 BCKDHB (branched-chain keto acid dehydrogenase e1, beta polypeptide) (eg, maple syrup urine disease) gene analysis, common variants (eg, r183p, g278s, e422x)
- **81206** BCR/ABL1 (t(9;22)) (eg, chronic myelogenous leukemia) translocation analysis; major breakpoint, qualitative or quantitative
- **81207** BCR/ABL1 (t(9;22)) (eg, chronic myelogenous leukemia) translocation analysis; minor breakpoint, qualitative or quantitative
- **81208** BCR/ABL1 (t(9;22)) (eg, chronic myelogenous leukemia) translocation analysis; other breakpoint, qualitative or quantitative
- **81209** BLM (bloom syndrome, recq helicase-like) (eg, bloom syndrome) gene analysis, 2281del6ins7 variant
- 81210 BRAF (v-raf murine sarcoma viral oncogene homolog b1) (eg, colon cancer), gene analysis, v600e variant
- BRCA1, BRCA2 (breast cancer 1 and 2) (eg, hereditary breast and ovarian cancer) gene analysis; full sequence analysis and common duplication/deletion variants in brca1 (ie, exon 13 del 3.835kb, exon 13 dup 6kb, exon 14-20 del 26kb, exon 22 del 510bp, exon 8-9 del 7.1kb)
- 81212 BRCA1, BRCA2 (breast cancer 1 and 2) (eg, hereditary breast and ovarian cancer) gene analysis; 185delag, 5385insc, 6174delt variants
- BRCA1 (breast cancer 1) (eg, hereditary breast and ovarian cancer) gene analysis; full sequence analysis and common duplication/deletion variants (ie,exon 13 del 3.835kb, exon 13 dup 6kb, exon 14-20 del 26kb, exon 22 del 510bp, exon 8-9 del 7.1kb)
- 81215 BRCA1 (breast cancer 1) (eg, hereditary breast and ovarian cancer) gene analysis; known familial variant
- **81216** BRCA2 (breast cancer 2) (eg, hereditary breast and ovarian cancer) gene analysis; full sequence analysis
- **81217** BRCA2 (breast cancer 2) (eg, hereditary breast and ovarian cancer) gene analysis; known familial variant
- 81220 CFTR (cystic fibrosis transmembrane conductance regulator) (eg, cystic fibrosis) gene analysis; common variants (eg, acmg/acog guidelines)
- 81221 CFTR (cystic fibrosis transmembrane conductance regulator) (eg, cystic fibrosis) gene analysis; known familial variants
- **81222** CFTR (cystic fibrosis transmembrane conductance regulator) (eg, cystic fibrosis)

CODE	DESCRIPTION
81223	gene analysis; duplication/deletion variants CFTR (cystic fibrosis transmembrane conductance regulator) (eg, cystic fibrosis)
	gene analysis; full gene sequence
81224	CFTR (cystic fibrosis transmembrane conductance regulator) (eg, cystic fibrosis)
81228	gene analysis; intron 8 poly-t analysis (eg, male infertility)  Cytogenomic constitutional (genome-wide) microarray analysis; interrogation of
	genomic regions for copy number variants (eg, bacterial artificial chromosome [bac] or oligo-based comparative genomic hybridization [cgh] microarray analysis)
81229	Cytogenomic constitutional (genome-wide) microarray analysis; interrogation of
	genomic regions for copy number and single nucleotide polymorphism (snp)
81235	variants for chromosomal abnormalities EGFR(epidermal growth factor receptor) (eg, non-small cell lung cancer) gene
01233	analysis, common variants (eg, exon 19 lrea deletion, l858r, t790m, g719a, g719s,
	l861q)
81240	F2 (prothrombin, coagulation factor ii) (eg, hereditary hypercoagulability) gene analysis, 20210g>a variant
81241	F5 (coagulation factor v) (eg, hereditary hypercoagulability) gene analysis, leiden
	variant
81242	FANCC (fanconi anemia, complementation group c) (eg, fanconi anemia, type c)
81243	gene analysis, common variant (eg, ivs4+4a>t) FMR1 (fragile x mental retardation 1) (eg, fragile x mental retardation) gene
0.2.0	analysis; evaluation to detect abnormal (eg, expanded) alleles
81244	FMR1 (fragile x mental retardation 1) (eg, fragile x mental retardation) gene
81245	analysis; characterization of alleles (eg, expanded size and methylation status) FLT3 (fms-related tyrosine kinase 3) (eg, acute myeloid leukemia), gene analysis,
012-10	internal tandem duplication (itd) variants (ie, exons 14, 15)
81250	G6PC (glucose-6-phosphatase, catalytic subunit) (eg, glycogen storage disease,
81251	type 1a, von gierke disease) gene analysis, common variants (eg, r83c, q347x) GBA (glucosidase, beta, acid) (eg, gaucher disease) gene analysis, common
01231	variants (eg, n370s, 84gg, l444p, ivs2+1g>a)
81252	GJB2 (gap junction protein, beta 2, 26kda; connexin 26) (eg, nonsyndromic hearing
81253	loss) gene analysis; full gene sequence
81254	GJB2 (gap junction protein, beta 2, 26kda; known familial variants GJB6 (gap junction protein, beta 6, 30kda, connexin 30) (eg, nonsyndromic hearing
	loss) gene analysis, common variants (eg, 309kb [del(gjb6-d13s1830)] and 232kb
04055	[del(gjb6-d13s1854)])
81255	HEXA (hexosaminidase a [alpha polypeptide]) (eg, tay-sachs disease) gene analysis, common variants (eg, 1278instatc, 1421+1g>c, g269s)
81257	HBA1/HBA2 (alpha globin 1 and alpha globin 2) (eg, alpha thalassemia, hb bart
	hydrops fetalis syndrome, hbh disease), gene analysis, for common deletions or
	variant (eg, southeast asian, thai, filipino, mediterranean, alpha3.7, alpha4.2, alpha20.5, and constant spring)
81260	IKBKAP (inhibitor of kappa light polypeptide gene enhancer in b-cells, kinase
	complex-associated protein) (eg, familial dysautonomia) gene analysis, common
81275	variants (eg, 2507+6t>c, r696p) KRAS (v-ki-ras2 kirsten rat sarcoma viral oncogene) (eg, carcinoma) gene
01213	111110 (v M-1432 Misteri iat sarcoma viiai oncogene) (eg, carcinoma) gene

CODE	DESCRIPTION
81280	analysis, variants in codons 12 and 13 Long qt syndrome gene analyses (eg, kcnq1, kcnh2, scn5a, kcne1, kcne2, kcnj2, cacna1c, cav3, scn4b, akap, snta1, and ank2); full sequence analysis
81281	Long qt syndrome gene analyses (eg, kcnq1, kcnh2, scn5a, kcne1, kcne2, kcnj2, cacna1c, cav3, scn4b, akap, snta1, and ank2); known familial sequence variant
81282	Long qt syndrome gene analyses (eg, kcnq1, kcnh2, scn5a, kcne1, kcne2, kcnj2, cacna1c, cav3, scn4b, akap, snta1, and ank2); duplication/deletion variants
81290	MCOLN1 (mucolipin 1) (eg, mucolipidosis, type iv) gene analysis, common variants (eg, ivs3-2a>g, del6.4kb)
81292	MLH1 (mutl homolog 1, colon cancer, nonpolyposis type 2) (eg, hereditary non-polyposis colorectal cancer, lynch syndrome) gene analysis; full sequence analysis
81293	MLH1 (mutl homolog 1, colon cancer, nonpolyposis type 2) (eg, hereditary non-polyposis colorectal cancer, lynch syndrome) gene analysis; known familial variants
81294	MLH1 (mutl homolog 1, colon cancer, nonpolyposis type 2) (eg, hereditary non-polyposis colorectal cancer, lynch syndrome) gene analysis; duplication/deletion variants
81295	MSH2 (muts homolog 2, colon cancer, nonpolyposis type 1) (eg, hereditary non-polyposis colorectal cancer, lynch syndrome) gene analysis; full sequence analysis
81296	MSH2 (muts homolog 2, colon cancer, nonpolyposis type 1) (eg, hereditary non-polyposis colorectal cancer, lynch syndrome) gene analysis; known familial variants
81297	MSH2 (muts homolog 2, colon cancer, nonpolyposis type 1) (eg, hereditary non-polyposis colorectal cancer, lynch syndrome) gene analysis; duplication/deletion variants
81298	MSH6 (muts homolog 6 [e. coli]) (eg, hereditary non-polyposis colorectal cancer, lynch syndrome) gene analysis; full sequence analysis
81299	MSH6 (muts homolog 6 [e. coli]) (eg, hereditary non-polyposis colorectal cancer, lynch syndrome) gene analysis; known familial variants
81300	MSH6 (muts homolog 6 [e. coli]) (eg, hereditary non-polyposis colorectal cancer, lynch syndrome) gene analysis; duplication/deletion variants
81301	Microsatellite instability analysis (eg, hereditary non-polyposis colorectal cancer, lynch syndrome) of markers for mismatch repair deficiency (eg, bat25, bat26), includes comparison of neoplastic and normal tissue, if performed
81302	MECP2 (methyl cpg binding protein 2) (eg, rett syndrome) gene analysis; full sequence analysis
81303	MECP2 (methyl cpg binding protein 2) (eg, rett syndrome) gene analysis; known familial variant
81304	MECP2 (methyl cpg binding protein 2) (eg, rett syndrome) gene analysis; duplication/deletion variants

CODE	DESCRIPTION
81310	NPM1 (nucleophosmin) (eg, acute myeloid leukemia) gene
81315	analysis, exon 12 variants PML/RARALPHA, (t(15;17)), (promyelocytic leukemia/retinoic acid
	receptor alpha) (eg, promyelocytic leukemia) translocation analysis; common breakpoints (eg, intron 3 and intron 6),
	qualitative or quantitative
81316	PML/RARALPHA, (t(15;17)), (promyelocytic leukemia/retinoic acid receptor alpha) (eg, promyelocytic leukemia) translocation
	analysis; single breakpoint (eg, intron 3, intron 6 or exon 6),
81317	qualitative or quantitative PMS2 (postmeiotic segregation increased 2 [s. cerevisiae]) (eg,
01317	hereditary non-polyposis colorectal cancer, lynch syndrome) gene
01210	analysis; full sequence analysis
81318	PMS2 (postmeiotic segregation increased 2 [s. cerevisiae]) (eg, hereditary non-polyposis colorectal cancer, lynch syndrome) gene analysis; known familial variants
81319	PMS2 (postmeiotic segregation increased 2 [s. cerevisiae]) (eg, hereditary non-
	polyposis colorectal cancer, lynch syndrome) gene analysis; duplication/deletion variants
81321	PTEN (phosphatase and tensin homolog) (eg, cowden syndrome, pten hamartoma
81322	tumor syndrome) gene analysis; full sequence analysis PTEN (phosphatase and tensin homolog) (eg, cowden syndrome, pten hamartoma
	tumor syndrome) gene analysis; known familial variant
81323	PTEN (phosphatase and tensin homolog) (eg, cowden syndrome, pten hamartoma tumor syndrome) gene analysis; duplication/deletion variant
81330	SMPD1(sphingomyelin phosphodiesterase 1, acid lysosomal) (eg, niemann-pick
81331	disease, type a) gene analysis, common variants (eg, r496l, l302p, fsp330)
01331	SNRPN/UBE3A (small nuclear ribonucleoprotein polypeptide n and ubiquitin protein ligase e3a) (eg, prader-willi syndrome and/or angelman syndrome),
04000	methylation analysis
81332	SERPINA1 (serpin peptidase inhibitor, clade a, alpha-1 antiproteinase, antitrypsin, member 1) (eg, alpha-1-antitrypsin deficiency), gene analysis, common variants
04050	(eg, *s and *z)
81350	UGT1A1 (udp glucuronosyltransferase 1 family, polypeptide a1) (eg, irinotecan metabolism), gene analysis, common variants (eg, *28, *36, *37)
81355	VKORC1 (vitamin k epoxide reductase complex, subunit 1) (eg, warfarin
81400	metabolism), gene analysis, common variants (eg, -1639/3673)  Molecular pathology procedure, level 1 (eg, identification of single germline variant
01400	[eg, snp] by techniques such as restriction enzyme digestion or melt curve
81401	analysis) Molecular pathology procedure, level 2 (eg, 2-10 snps, 1 methylated variant, or 1
01401	somatic variant [typically using nonsequencing target variant analysis], or detection
04.400	of a dynamic mutation disorder/triplet repeat)
81402	Molecular pathology procedure, level 3 (eg, >10 snps, 2-10 methylated variants, or 2-10 somatic variants [typically using non-sequencing target variant analysis],
	immunoglobulin and t-cell receptor gene rearrangements, duplication/deletion variants 1 exon)
	variante i Gaurij

CODE	DESCRIPTION
81403	Molecular pathology procedure, level 4 (eg, analysis of single exon by dna sequence analysis, analysis of >10 amplicons using multiplex pcr in 2 or more independent reactions, mutation scanning or duplication/deletion variants of 2-5 exons)
81404	Molecular pathology procedure, level 5 (eg, analysis of 2-5 exons by dna sequence analysis, mutation scanning or duplication/ deletion variants of 6-10 exons, or characterization of a dynamic mutation disorder/triplet repeat by southern blot analysis)
81405	Molecular pathology procedure, level 6 (eg, analysis of 6-10 exons by dna sequence analysis, mutation scanning or duplication/ deletion variants of 11-25 exons)
81406	Molecular pathology procedure, level 7 (eg, analysis of 11-25 exons by dna sequence analysis, mutation scanning or duplication/deletion variants of 26-50 exons, cytogenomic array analysis for neoplasia)
81407	Molecular pathology procedure, level 8 (eg, analysis of 26-50 exons by dna sequence analysis, mutation scanning or duplication/deletion variants of >50 exons, sequence analysis of multiple genes on one platform)
81408	Molecular pathology procedure, level 9 (eg, analysis of >50 exons in a single gene by dna sequence analysis)
81479	Unlisted molecular pathology procedure

## MULTIANALYTE ASSAYS WITH ALGORITHMIC ANALYSES

81508	Fetal congenital abnormalities, biochemical assays of two proteins (papp-a,
	hcg[any form]), utilizing maternal serum, algorithm reported as a risk score
81509	Fetal congenital abnormalities, biochemical assays of three proteins (papp-a,
	hcg [any form], dia), utilizing maternal serum, algorithm reported as a risk score
81510	Fetal congenital abnormalities, biochemical assays of three analytes (afp,
	ue3,hcg [any form]), utilizing maternal serum, algorithm reported as a risk score
81511	Fetal congenital abnormalities, biochemical assays of four analytes (afp, ue3,
	hcg [any form], dia) utilizing maternal serum, algorithm reported as a risk score
	(may include additional results from previous biochemical testing)
81512	Fetal congenital abnormalities, biochemical assays of five analytes (afp, ue3,
	total hcg, hyperglycosylated hcg, dia) utilizing maternal serum, algorithm
	reported as a risk score

## **CHEMISTRY**

Ketone body(s) (eg, acetone, acetoacetic acid, beta-
hydroxybutyrate); qualitative
Acetylcholinesterase
Acylcarnitines; qualitative, each specimen
quantitative, each specimen

CODE	DESCRIPTION
82024	Adrenocorticotropic hormone (ACTH)
82040	Albumin; serum, plasma or whole blood (see Rule 11)
82042	urine or other source, quantitative, each specimen (see Rule 11)
82043	urine, microalbumin, quantitative (see Rule 11)
82044	urine, microalbumin, semiquantitative (e.g., reagent strip assay)
	(see Rule 11)
82045	ischemia modified
82088	Aldosterone
82103	Alpha-1-antitrypsin; total
82104	phenotype
82105	Alpha-fetoprotein (AFP); serum
82106	amniotic fluid
82107	AFP-L3 fraction isoform and total AFP (including ratio)
82108	Aluminum
82120	Amines, vaginal fluid, qualitative
82127	Amino acids; single, qualitative, each specimen (not elsewhere specified)
82128	multiple, qualitative, each specimen (not elsewhere specified)
82131	single, quantitative, each specimen, (not elsewhere specified)
82136	Amino acids, 2 to 5 amino acids, quantitative, each specimen
82139	Amino acids, 6 or more amino acids, quantitative, each
	specimen
82140	Ammonia (blood)
82143	Amniotic fluid scan (spectrophotometric)
82150	Amylase (see Rule 11)
82154	Androstanediol glucuronide
82157	Androstenedione
82172	Apolipoprotein, each (see Rule 16)
82175	Arsenic
82180	Ascorbic acid (Vitamin C), blood
82205	Barbiturates, not elsewhere specified (therapeutic monitoring only)
	(see Rule 5)
82232	Beta-2 microglobulin
82239	Bile acids; total
82240	cholylglycine
82247	Bilirubin; total (see Rule 11)
82248	direct (see Rule 11)
82261	Biotinidase, each specimen
82270	Blood, occult, by peroxidase activity (e.g., guaiac), qualitative; feces,
	consecutive collected specimens with single determination, for colorectal
	neoplasm screening (e.g., patient was provided three cards or single triple
00074	card for consecutive collection)
82274	Blood, occult, by fecal hemoglobin determination by immunoassay,
00000	qualitative, feces, 1-3 simultaneous determinations
82300	Cadmium Vitamin D. 25 bydrovy, includes fraction(s), if performed
82306	Vitamin D; 25 hydroxy, includes fraction(s), if performed
82308	Calcitonin

CODE	DESCRIPTION
82310	Calcium; total (see Rule 11)
82330	ionized (see Rule 11)
82340	urine quantitative, timed specimen (see Rule 11)
82355	Calculus; qualitative analysis
82360	quantitative analysis, chemical
82365	infrared spectroscopy
82370	x-ray diffraction
82373	Carbohydrate deficient transferrin
82374	Carbon dioxide (bicarbonate) (see Rule 11)
82375	Carboxyhemoglobin; quantitative
82378	Carcinoembryonic antigen (CEA) (see Rule 15)
82379	Carnitine (total and free), quantitative, each specimen
82382	Catecholamines; total urine
82383	blood
82384	fractionated
82390	Ceruloplasmin
82435	Chloride; blood (see Rule 11)
82436	urine (see Rule 11)
82438	other source (see Rule 11)
82465	Cholesterol, serum or whole blood, total (see Rule 11)
82480	Cholinesterase; serum
82495	Chromium
82507 82523	Citrate
82525	Collagen cross links, any method Copper
82530	Cortisol; free
82533	total
82550	Creatine kinase (CK),(CPK); total (see Rule 11)
82552	isoenzymes
82553	MB fraction only
82565	Creatinine; blood (see Rule 11)
82570	other source (see Rule 11)
82575	clearance (see Rule 11)
82595	Cryoglobulin, qualitative or semi-quantitative (e.g., cryocrit)
82607	Cyanocobalamin (Vitamin B-12); (see Rule 6B)
82608	unsaturated binding capacity
82615	Cystine and homocystine, urine, qualitative
82626	Dehydroepiandrosterone (DHEA)
82627	Dehydroepiandrosterone-sulfate (DHEA-S)
82634	Deoxycortisol, 11-
82656	Elastase, pancreatic (EL-1), fecal, qualitative or semi-
	quantitative
82668	Erythropoietin
82670	Estradiol
82672	Estrogens; total
82677	Estriol

CODE	DESCRIPTION
82679	Estrone
82705	Fat or lipids, feces; qualitative
82710	quantitative
82726	Very long chain fatty acids
82728	Ferritin
82731	Fetal fibronectin, cervicovaginal secretions, semi-quantitative
82746	Folic acid; serum (see Rule 6B)
82747	RBC (see Rule 6B)
82759	Galactokinase, RBC
82760	Galactose
82775	Galactose-1-phosphate uridyl transferase; quantitative
82784	Gammaglobulin (immunoglobulin); IgA, IgD, IgG, IgM, each
82785	IgE
82787	immunoglobulin subclasses (eg, IgG1, 2, 3 or 4), each
82803	Gases, blood, any combination of (two or more) pH, pC02, p02, C02, HC03 (including calculated 02 saturation);
82805	with 02 saturation, by direct measurement, except pulse oximetry
82810	Gases, blood, O2 saturation only, by direct measurement, except pulse
	oximetry
82820	Hemoglobin-oxygen affinity (pO2 for 50% hemoglobin saturation with
	oxygen)
82938	Gastrin after secretin stimulation
82941	Gastrin
82943	Glucagon
82945	Glucose, body fluid, other than blood (see Rule 11)
82947	Glucose; quantitative, blood (except reagent strip) (see Rule 11)
82948	blood, reagent strip
82950	post glucose dose (includes glucose)
82951	tolerance test (GTT), three specimens (includes glucose)
82952	tolerance test, each additional beyond 3 specimens
	(List separately in addition to code for primary procedure)
	(Use 82952 in conjunction with 82951)
82953	tolbutamide tolerance test (glucose x 7 and insulin x 7) (includes
	glucose, for more information see Evocative/Suppression Testing
	Section)
82955	Glucose-6-phosphate dehydrogenase (G6PD); quantitative
82960	screen
82963	Glucosidase, beta
82965	Glutamate dehydrogenase
82977	Glutamyltransferase, gamma (GGT) (see Rule 11)
82980	Glutethimide
82985	Glycated protein
83001	Gonadotropin; follicle stimulating hormone (FSH)
83002	luteinizing hormone (LH)
83003	Growth hormone, human (HGH) (somatotropin)

CODE	DESCRIPTION
83009	Helicobacter pylori, blood test analysis for urease activity, non-radioactive isotope (e.g., C-13) (includes kit)
83010	Haptoglobin; quantitative
83013	Helicobacter pylori; breath test analysis for urease activity, non-radioactive isotope (includes kit)
83015	Heavy metal (arsenic, barium, beryllium, bismuth, antimony, mercury); screen
83020	Hemoglobin fractionation and quantitation; electrophoresis (e.g., A2, S, C, and/or F)
83021	chromatography (e.g., A2, S, C, and/or F)
83030	Hemoglobin; F (fetal), chemical
83036	glycosylated (A1C)
83050	methemoglobin, quantitative
83051	plasma
83080	b-Hexosaminidase, each assay (Tay Sachs diagnostic/carrier testing)
83090	Homocystine
83150	Homovanillic acid (HVA)
83497	Hydroxyindolacetic acid, 5-(HIAA)
83498	Hydroxyprogesterone, 17-d
83500	Hydroxyproline; free
83505	total
83525	Insulin; total
83527	free
83540	Iron (see Rule 11)
83550	Iron binding capacity (see Rule 11)
83586	Ketosteroids, 17- (17-KS); total
83593	fractionation
83605	Lactate (lactic acid)
83615	Lactate dehydrogenase (LD), (LDH); (see Rule 11)
83625	isoenzymes, separation and quantitation
83630	Lactoferrin, fecal; qualitative
83631	quantitative
83655	Lead
83661	Fetal lung maturity assessment; lecithin sphingomyelin (L/S) ratio
83662	foam stability test
83663	fluorescence polarization
83664	lamellar body density
83690	Lipase
83718	Lipoprotein, direct measurement; high density cholesterol (HDL cholesterol) (see Rule 11)
83727	Luteinizing releasing factor (LRH)
83735	Magnesium (see Rule 11)
83785	Manganese
83825	Mercury, quantitative
83835	Metanephrines
83858	Methsuximide
83864	Mucopolysaccharides, acid; quantitative

CODE	DESCRIPTION
83866	screen
83876	Myeloperoxidase (MPO)
83880	Natriuretic peptide
83918	Organic acids; total, quantitative, each specimen
83919	qualitative, each specimen
83921	Organic acid, single, quantitative
83930	Osmolality; blood (see Rule 4)
83935	urine (see Rule 4)
83945	Oxalate
83950	Oncoprotein; HER-2/neu (see Rule 15)
83951	des-gamma-carboxy-prothrombin (DCP)
83970	Parathormone (parathyroid hormone)
83993	Calprotectin, fecal
84030	Phenylalanine (PKU), blood
84060	Phosphatase, acid; total (see Rule 11)
84066	prostatic (see Rule 15)
84075	Phosphatase, alkaline; (see Rule 11)
84078	heat stable (total not included) (see Rule 11)
84080	isoenzymes
84081	Phosphatidylglycerol (separate procedure)
84087	Phosphohexose isomerase
84100	Phosphorus inorganic (phosphate); (see Rule 11)
84105	urine (see Rule 11)
84106	Porphobilinogen, urine; qualitative
84110	quantitative
84112	Placental alpha microglobulin-1 (PAMG-1), cervicovaginal secretion, qualitative
84119 84120	Porphyrins, urine; qualitative quantitation and fractionation
84132	Potassium; serum, plasma or whole blood (see Rule 11)
84133	urine (see Rule 11)
84134	Prealbumin
84140	Pregnenolone
84143	17-hydroxypregnenolone
84144	Progesterone
84146	Prolactin
84152	Prostate specific antigen (PSA); complexed (direct
	measurement)
84153	total (see Rule 15)
84154	free (see Rule 15)
84155	Protein, total, except by refractometry; serum, plasma or whole blood
	(see Rule 11)
84156	urine (see Rule 11)
84157	other source (e.g., synovial fluid, cerebrospinal fluid) (see Rule 11)
84160	Protein, total, by refractometry, any source (see Rule 11)
84163	Pregnancy-associated plasma protein-A (PAPP-A)
84165	Protein; electrophoretic fractionation and quantitation, serum

CODE	DESCRIPTION
84166	electrophoretic fractionation and quantitation, other fluids with concentration (e.g., urine, CSF)
84202	Protoporphyrin, RBC; quantitative
84207	Pyridoxal phosphate (Vitamin B-6)
84220	Pyruvate kinase
84233	Receptor assay; estrogen
84234	progesterone
84275	Sialic acid
84295	Sodium; serum, plasma or whole blood (see Rule 11)
84300	urine (see Rule 11)
84302	other source
84305	Somatomedin
84375	Sugars, chromatographic, TLC or paper chromatography
84376	Sugars (mono-,di-, and oligosaccharides); single qualitative, each specimen
84377	multiple qualitative, each specimen
84378	single quantitative, each specimen
84379	multiple quantitative, each specimen
84402	Testosterone; free
84403	total
84425	Thiamine (Vitamin B-1)
84436	Thyroxine; total
84439	free
84442	Thyroxine binding globulin (TBG)
84443	Thyroid stimulating hormone (TSH)
84446	Tocopherol alpha (Vitamin E)
84449	Transcortin (cortisol binding globulin)
84450	Transferase; aspartate amino (AST) (SGOT) (see Rule 11)
84460	alanine amino (ALT) (SGPT) (see Rule 11)
84466	Transferrin
84478	Triglycerides (see Rule 11)
84479	Thyroid hormone (T3 or T4) uptake (with or without) thyroid hormone binding
84480	ratio (THBR)
84481	Triiodothyronine T3; total (TT-3) free
84482	reverse
84484	Troponin, quantitative
84510	Tyrosine
84512	Troponin, qualitative
84520	Urea nitrogen; quantitative (see Rule 11)
84540	urine (see Rule 11)
84550	Uric acid; blood (see Rule 11)
84560	other source (see Rule 11)
84585	Vanillylmandelic acid (VMA), urine
84588	Vasopressin (antidiuretic hormone, ADH)
84590	Vitamin A
84591	Vitamin, not otherwise specified

CODE	DESCRIPTION
84597	Vitamin K
84620	Xylose absorption test, blood and/or urine
84630	Zinc
84681	C-peptide
84702	Gonadotropin, chorionic (hCG); quantitative (see Rules 9 and 15)
84703	qualitative (see Rule 9)
84704	free beta chain
84999	Unlisted chemistry/genetic testing procedure (see Rule 3)
	(Reimbursement is limited to the listed analytes for the purpose of providing
	information for diagnosis or monitoring of genetic disease or carrier state.
	Clinical applications other than genetic testing are subject to a coverability
	determination for unlisted procedures.)

Acetylglucosamidase, Fumarase Neuraminidase Alpha N-Galactocerebrosidase. Beta Nucleoside Phosphorylase Acid Maltase Galactose -4- Sulfatase Ornithine Carbamyl Acyl-CoA Dehydrogenase, Galactose -6- Sulfatase Transferase (OCT) Galactosidase, Alpha Phosphofructokinase Medium Chain **Short Chain** and/or Beta Phosphoglucomutase, Adenosine deaminase Glucocerebrosidase, Beta Isoenzymes Adenylate kinase Glucuronidase, Beta Phosphoglycerate Kinase Glyceraldehyde -3-P-Phosphoglycerate Mutase Aldolase Arginosuccinase Dehydrogenase Phosphorylase Phosphorylase B Kinase Arylsulfatase A,B and/or C Glycerophosphate Dehydrogenase, **ATPase** Alpha Phytanic acid Citrate Synthase Hexosaminidase, A Pyruvate Decarboxylase Cytochrome Oxidase Iduronidase, alpha Sphingomyelinase Dihydropteridine Reductase Iduronosulfatase Succinate Cytochrome C Dystrophin Mannosidase, Alpha and/or Beta Reductase Enolase Myoadenylate Deaminase Succinate Dehydrogenase Fatty Acids, Long Chain NADH Cytochrome C Reductase Sulfaminidase Fucosidase, Alpha and/or Beta NADH Dehydrogenase Triose phosphate Isomerase

## **HEMATOLOGY and COAGULATION**

85002	Bleeding time
85004	Blood count; automated differential WBC count
85007	blood smear, microscopic examination with manual differential WBC count
	(includes RBC morphology and platelet estimation)
85013	spun microhematocrit
85014	hematocrit
85018	hemoglobin (Hgb)
85025	complete (CBC), automated (Hgb, Hct, RBC, WBC and platelet count), and
	automated differential WBC count
85027	complete (CBC), automated (Hgb, Hct, RBC, WBC and platelet count)
85032	manual cell count (erythrocyte, leukocyte, or platelet) each
85041	red blood cell (RBC), automated
85044	reticulocyte, manual
85045	reticulocyte, automated
85046	reticulocytes, automated, including one or more cellular parameters (e.g.
	reticulocyte hemoglobin content (CHr), immature reticulocyte volume
	(MRV), RNA content), direct measurement

CODE	DESCRIPTION
85048	leukocyte (WBC), automated
85049	platelet, automated
85055	Reticulated platelet assay
85060	Blood smear, peripheral, (including) interpretation by physician with written report
85097	Bone marrow; smear interpretation
85210	Clotting; factor II, prothrombin, specific
85220	factor V (AcG or proaccelerin), labile factor
85230	factor VII (proconvertin, stable factor)
85240	factor VIII (AHG), one stage
85244	factor VIII related antigen
85245	factor VIII, VW factor, ristocetin cofactor
85246	factor VIII, VW factor antigen
85247	factor VIII, Von Willebrand factor, multimetric analysis
85250	factor IX (PTC or Christmas)
85260	factor X (Stuart-Prower)
85270	factor XI (PTA)
85280	factor XII (Hageman)
85290	factor XIII (fibrin stabilizing)
85291	factor XIII (fibrin stabilizing), screen solubility
85292	prekallikrein assay (Fletcher factor assay)
85293	high molecular weight kininogen assay (Fitzgerald factor assay)
85300	Clotting inhibitors or anticoagulants; antithrombin III, activity
85301	antithrombin III, antigen assay
85302	protein C, antigen
85303	protein C, activity
85305	protein S, total
85306	protein S, free
85307	Activated Protein C (APC) resistance assay
85335	Factor inhibitor test
85337	Thrombomodulin
85347	Coagulation time; activated
85348	other methods
85360	Euglobulin lysis
85362	Fibrin(ogen) degradation (split) products (FDP) (FSP); agglutination slide,
	semiquantitative
85366	paracoagulation
85370	quantitative
85378	Fibrin degradation products, D-dimer; qualitative or semiquantitative
85379	quantitative
85380	ultrasensitive (e.g., for evaluation for venous thromboembolism), qualitative or semiquantitative
85384	Fibrinogen; activity
85385	antigen
85397	Coagulation and fibrinolysis, functional activity, not otherwise specified (eg,
05444	ADAMTS-13), each analyte
85441	Heinz bodies; direct

CODE	DESCRIPTION
85445	induced, acetyl phenylhydrazine
85460	Hemoglobin or RBCs, fetal, for fetomaternal hemorrhage; differential lysis (Kleihauer-Betke)
85461	rosette
85475	Hemolysin, acid
85520	Heparin assay
85536	Iron stain, peripheral blood
85540	Leukocyte alkaline phosphatase with count
85549	Muramidase
85555	Osmotic fragility, RBC; unincubated
85557	incubated
85576	Platelet; aggregation (in vitro), each agent
85610	Prothrombin time
85612	Russell viper venom time (includes venom); undiluted
85613	diluted
85635	Reptilase test
85651	Sedimentation rate, erythrocyte; non-automated
85652	automated
85670	Thrombin time; plasma
85705	Thromboplastin inhibition; tissue
85730	Thromboplastin time, partial (PTT); plasma or whole blood
85732	substitution, plasma fractions, each
85810	Viscosity

## **IMMUNOLOGY**

Immunologic tests for antigen or antibody should be reported using the most specific code available. For infectious agent antibody or antigen tests, see codes 86602 – 86793 and the cross-references located in that coding range. See Rules 6 and 10. For antigen identification in solid tissue, see 88342-88347 in Surgical Pathology.

86038	Antinuclear antibodies (ANA);
86039	titer
86060	Antistreptolysin 0; titer
86063	screen
86140	C-reactive protein;
86141	high sensitivity (hsCRP)
86146	Beta 2 Glycoprotein 1 antibody, each
86147	Cardiolipin (phospholipid) antibody, each Ig class
86148	Anti-phosphatidylserine (phospholipid) antibody
86157	Cold agglutinin; titer
86160	Complement; antigen, each component
86161	functional activity, each component
86162	total hemolytic (CH50)
86215	Deoxyribonuclease, antibody

CODE	DESCRIPTION
86225 86235	Deoxyribonucleic acid (DNA) antibody; native or double stranded Extractable nuclear antigen, antibody to, any method (e.g., nRNP, SS-A, SS-B, Sm, RNP, Scl70, J01), each antibody
86255	Fluorescent noninfectious agent antibody; screen, each antibody, (not elsewhere specified) (see Rule 10)
86256	titer, each antibody <b>(not elsewhere specified)</b> (see Rule 10)
86294	Immunoassay for tumor antigen, qualitative or semiquantitative (e.g., bladder tumor antigen) (see Rule 15)
86300	Immunoassay for tumor antigen, quantitative; CA 15-3 (27.29) (see Rule 15)
86301	CA 19-9 (see Rule 15)
86304	CA 125 (see Rule 15)
86305	Human epididymis protein 4 (HE4)
86308	Heterophile antibodies; screening
86309	titer
86316	Immunoassay for tumor antigen; other antigen, quantitative, (e.g., CA 50,72-4, 549), each (not elsewhere specified) (see Rule 15)
86318	Immunoassay for infectious agent antibody, qualitative or semiquantitative, single step method <b>(not elsewhere specified)</b> (e.g., reagent strip)
86320	Immunoelectrophoresis; serum
86325	other fluids (e.g., urine, cerebrospinal fluid) with concentration
86329	Immunodiffusion; not elsewhere specified
86334	Immunofixation electrophoresis; serum
86335	other fluids with concentration (e.g., urine, CSF)
86336	Inhibin A
86337	Insulin antibodies
86340	Intrinsic factor antibodies
86341	Islet cell antibody (see Rule 19)
86355	B cells, total count (see Rule 18)
86357 86359	Natural killer (NK) cells, total count (see Rule 18)  T cells; total count
86360	absolute CD4 and CD8 count, including ratio
86361	absolute CD4 and CD6 count, including ratio
00001	
	(For T-cell immunophenotyping, see Rule 18)
86367	Stem cells (e.g., CD34), total count (see Rule 18)
86376	Microsomal antibodies (e.g., thyroid or liver-kidney), each
86382	Neutralization test, viral
86403	Particle agglutination; screen, each antibody
86430	Rheumatoid factor; qualitative
86431	quantitative
86480	Tuberculosis test, cell mediated immunity antigen response measurement; gamma interferon
86481	enumeration of gamma interferon-producing T-cells in cell suspension
86592 86593	Syphilis test, non-treponemal antibody; qualitative (e.g., VDRL, RPR, ART) quantitative (includes screen and titer)

CODE	DESCRIPTION
	(For infectious agent antibody or antigen tests not listed by name, see Rule 10 A, B; for maximum reimbursable amounts for two or more infectious agent tests, see Rule 6C.)
86602	Antibody; actinomyces
86603	adenovirus
86606	Aspergillus
86609	bacterium, not elsewhere specified
86611	Bartonella
86612	Blastomyces
86615	Bordetella
86617	Borrelia burgdorferi (Lyme disease) confirmatory test (e.g., Western blot or immunoblot)
86618	Borrelia burgdorferi (Lyme disease)
86619	Borrelia (relapsing fever)
86622	Brucella
86625	Campylobacter
86631	Chlamydia
86632	Chlamydia, IgM
86635 86638	Coccidioides Coxiella brunetii (Q fever)
86641	Cryptococcus
86644	cytomegalovirus (CMV)
86645	cytomegalovirus (CMV), IgM
86651	encephalitis, California (La Crosse)
86652	encephalitis, Eastern equine
86653	encephalitis, St. Louis
86654	encephalitis, Western equine
86658	enterovirus (e.g., coxsackie, echo, polio)
86663 86664	Epstein-Barr (EB) virus, early antigen (EA)
86665	Epstein-Barr (EB) virus, nuclear antigen (EBNA) Epstein-Barr (EB) virus, viral capsid (VCA)
86666	Ehrlichia
86668	Francisella tularensis
86671	fungus, not elsewhere specified
86674	Giardia lamblia
86677	Helicobacter pylori
86682	helminth, not elsewhere specified
86684	Hemophilus influenza
86687	HTLV-I
86689	HTLV or HIV antibody, confirmatory test (e.g., Western Blot)
86692 86696	hepatitis, delta agent herpes simplex, type 2
86698	histoplasma
86701	HIV-1
86702	HIV-2

CODE	<u>DESCRIPTION</u>
86703	HIV-1 and HIV-2, single result
	(For maximum reimbursable amounts for hepatitis tests performed in combination, see Rule 6C)
86704 86705 86706 86707 86708 86709 86710 86713 86717 86720 86723 86727 86729 86735 86738 86741 86744 86747 86750 86753 86756 86757 86759 86758 86765 86765 86765 86765 86771 86777 86778 86778 86778 86788	Hepatitis B core antibody (HBcAb), total IgM antibody Hepatitis B surface antibody (HBsAb) Hepatitis B antibody (HBeAb) Hepatitis A antibody (HAAb), total IgM antibody Antibody: influenza virus Legionella Leishmania Leptospira Listeria monocytogenes Iymphocytic choriomeningitis Iymphogranuloma venereum mumps mycoplasma Neisseria meningitidis Nocardia parvovirus Plasmodium (malaria) protozoa, not elsewhere specified respiratory syncytial virus Rickettsia rotavirus rubella rubeola Salmonella Shigella Toxoplasma Toxoplasma, IgM Treponema pallidum Trichinella varicella-zoster West Nile virus, IgM
86789 86790	West Nile virus virus, not elsewhere specified
86793	Yersinia
86800	Thyroglobulin antibody
86803	Hepatitis C antibody;
86804	confirmatory test (e.g., immunoblot)

## TRANSFUSION MEDICINE

CODE	<u>DESCRIPTION</u>
86850	Antibody screen, RBC, each serum technique
86860	Antibody elution (RBC), each elution
86870	Antibody identification, RBC antibodies, each panel for each serum technique
86880	Antihuman globulin test (Coombs test); direct, each antiserum
86900	Blood typing; ABO
86901	Rh (D)
86905	RBC antigens, other than ABO or Rh (D), each
86940	Hemolysins and agglutinins; auto, screen, each
86941	incubated

## **MICROBIOLOGY**

87015	Concentration (any type), for infectious agents
87040	Culture, bacterial; blood, aerobic, with isolation and presumptive identification of isolates (includes anaerobic culture, if appropriate)
87045	stool, aerobic, with isolation and preliminary examination (e.g., KIA, LIA), Salmonella and Shigella species
87046	stool, aerobic, additional pathogens, isolation and presumptive identification of isolates, each plate
87070	any other source except urine, blood or stool, aerobic, with isolation and presumptive identification of isolates
87075	any source, except blood, anaerobic with isolation and presumptive identification of isolates
87076	anaerobic isolate, additional methods required for definitive identification, each isolate
87077	aerobic isolate, additional methods required for definitive identification, each isolate
87081	Culture, presumptive, pathogenic organisms, screening only
87086	Culture, bacterial; quantitative colony count, urine
87088	with isolation and presumptive identification of each isolates, urine
87101	Culture, fungi (mold or yeast) isolation, with presumptive identification of isolates; skin, hair, or nail
87102	other source (except blood)
87103	blood
87106	Culture, fungi, definitive identification, each organism; yeast
	(Use in addition to codes 87101, 87102, or 87103 when appropriate)
87107	mold
87109	Culture, mycoplasma, any source
87110	Culture, chlamydia, any source
87116	Culture, tubercle or other acid-fast bacilli (e.g., TB, AFB, mycobacteria) any source, with isolation and presumptive identification of isolates
87118	Culture, mycobacterial, definitive identification, each isolate
87164	Dark field examination, any source (e.g., penile, vaginal, oral, skin); includes specimen collection
87166	without collection
87169	Macroscopic examination; parasite
	•

CODE	DESCRIPTION
87172	Pinworm exam (e.g., cellophane tape prep)
87177	Ova and parasites, direct smears, concentration and identification
87181	Susceptibility studies, antimicrobial agent; agar dilution method, per agent (e.g., antibiotic gradient strip)
87184	disk method, per plate (12 or fewer agents)
87185	enzyme detection (e.g., beta lactamase), per enzyme
87186	microdilution or agar dilution (minimum inhibitory concentration (MIC) or breakpoint), each multi-antimicrobial, per plate
87188	macrobroth dilution method, each agent
87190	mycobacteria, proportion method, each agent
87205	Smear, primary source with interpretation; Gram or Giemsa stain for bacteria, fungi or cell types
87206	fluorescent and/or acid fast stain for bacteria, fungi, parasites, viruses or cell types
87207	special stain for inclusion bodies or parasites (e.g., malaria, coccidia, microsporidia, trypanosomes, herpes viruses)
87209	complex special stain (e.g., trichrome, iron hemotoxylin) for ova and parasites
87210	wet mount for infectious agents (e.g., saline, India ink, KOH preps) (Does not include KOH on skin, hair or nails)
87230	Toxin or antitoxin assay, tissue culture (e.g., Clostridium difficile toxin)
87250	Virus isolation; inoculation of embryonated eggs, or small animal, includes observation and dissection
87252	tissue culture inoculation, observation, and presumptive identification by cytopathic effect
87253	tissue culture, additional studies or definitive identification (e.g., hemabsorption, neutralization, immunofluorescence stain), each isolate
87254	centrifuge enhanced (shell vial) technique, includes identification with immunofluorescence stain, each virus
87255	including identification by non-immunologic method, other than by cytopathic effect (e.g., virus specific enzymatic activity)
87260	Infectious agent antigen detection by immunofluorescent technique; adenovirus
87265	Bordetella pertussis/parapertussis
87269	giardia
87270	Chlamydia trachomatis
87271	Cytomegalovirus, direct fluorescent antibody (DFA)
87272	cryptosporidium
87273	Herpes simplex virus type 2
87274	Herpes simplex virus type 1
87275	influenza B virus
87276	influenza A virus
87278	Legionella pneumophila
87279	Parainfluenza virus, each type
87280	respiratory syncytial virus
87281	Pneumocystis carinii
87290	Varicella zoster virus

CODE	DESCRIPTION	
87299 87301	not otherwise specified, each organism (see Rule 10B) Infectious agent antigen detection by enzyme immunoassay technique, qualitative or semiquantitative, multiple step method; adenovirus enteric types 40/41	
87305	Aspergillus	
87320	Chlamydia trachomatis	
87324	Clostridium difficile toxin(s)	
87327	Cryptococcus neoformans	
87328	cryptosporidium	
87329	giardia	
87332 87335	cytomegalovirus Escherichia coli 0157	
87336	Entamoeba histolytica dispar group	
87337	Entamoeba histolytica group	
87338	Helicobacter pylori, stool	
87340	hepatitis B surface antigen (HBsAg)	
87341	hepatitis B surface antigen (HBsAg) neutralization	
87350	hepatitis Be antigen (HBeAg)	
87380	hepatitis, delta agent	
87389	Infectious agent antigen detection by enzyme immunoassay technique,	
	qualitativeor semiquantitative, multiple-step method; hiv-1 antigen(s), with hiv-1	
07200	and hiv-2 antibodies, single result	
87390 87420	HIV-1 (e.g., P24 antigen)	
87425	respiratory syncytial virus rotavirus	
87427	Shiga-like toxin	
87430	Streptococcus, group A	
87449	Infectious agent antigen detection by enzyme immunoassay technique	
	qualitative or semiquantitative; multiple step method, not otherwise specified,	
	each organism	
87450	single step method, not otherwise specified, each organism	
87476	Infectious agent detection by nucleic acid (DNA or RNA); Borrelia burgdorferi,	
07.400	amplified probe technique	
87480	Candida species, direct probe technique	
87486	Chlamydia pneumoniae, amplified probe technique	
87490 87491	Chlamydia trachomatis, direct probe technique Chlamydia trachomatis, amplified probe technique	
87495	Cytomegalovirus, direct probe technique	
87498	Enterovirus, reverse transcription and amplified probe technique	
87500	Vancomycin resistance (eg, enterococcus species van a, van b), amplified	
	probe technique	
87501	influenza virus, reverse transcription and amplified probe technique, each	
	type or subtype	
87502	influenza virus, for multiple types or sub-types, reverse transcription and	
	amplified probe technique, first 2 types or sub-types	
87503	influenza virus, for multiple types or sub-types, multiplex reverse	

CODE	DESCRIPTION
	transcription and amplified probe technique, each additional influenza virus type or sub-type beyond 2 (List separately in addition to code for primary procedure) (Use 87503 in conjunction with 87502)
87510	Gardnerella vaginalis, direct probe technique
87516	Hepatitis B virus, amplified probe technique
87521	Hepatitis C, reverse transcription and amplified probe technique
87522 87535	Hepatitis C, reverse transcription and quantification HIV-1, reverse transcription and amplified probe technique
87536	HIV-1, reverse transcription and quantification
87551	Mycobacteria species, amplified probe technique
87556	Mycobacteria tuberculosis, amplified probe technique
87561	Mycobacteria avium-intracellulare, amplified probe technique
87581	Mycoplasma pneumoniae, amplified probe technique
87590	Neisseria gonorrhoeae, direct probe technique
87591 87620	Neisseria gonorrhoeae, amplified probe technique papillomavirus, human, direct probe technique
87621	papillomavirus, human, amplified probe technique
87631	Infectious agent detection by nucleic acid (dna or rna); respiratory virus (eg,
	adenovirus, influenza virus, coronavirus, metapneumovirus, parainfluenza virus,
	respiratory syncytial virus, rhinovirus), multiplex reverse transcription and
	amplified probe technique, multiple types or subtypes, 3-5 targets
87640	Staphylococcus aureus, amplified probe technique
87641	Staphylococcus aureus, methicillin resistant, amplified probe technique (includes staphylococcus aureus identification)
87650	Streptococcus, group A, direct probe technique
0.000	on optioned and production in que
87653	Streptococcus, group B, amplified probe technique
87660	Trichomonas vaginalis, direct probe technique
87797	Infectious agent detection by nucleic acid (DNA or RNA), not otherwise
87798	specified; direct probe technique, each organism amplified probe technique, each organism
87800	Infectious agent detection by nucleic acid(DNA or RNA), multiple organisms;
0.000	direct probe(s) technique
87801	amplified probe(s) technique
87803	Infectious agent antigen detection by immunoassay with direct optical
	observation; Clostridium difficile toxin A
87804	influenza
87807 87808	respiratory syncytial virus Trichomonas vaginalis
87809	adenovirus
87880	Infectious agent detection by immunoassay with direct optical observation;
2.500	Streptococcus, group A
87899	not otherwise specified
87900	Infectious agent drug susceptibility phenotype prediction using regularly updated

CODE	DESCRIPTION
87901	genotypic bioinformatics Infectious agent genotype analysis by nucleic acid (DNA or RNA); HIV-1, reverse transcriptase and protease regions
87902 87903	Hepatitis C virus Infectious agent phenotype analysis by nucleic acid (DNA or RNA); HIV 1,
87904	through 10 drugs tested each additional drug tested (List separately in addition to primary procedure)
87906	Infectious agent genotype analysis by nucleic acid (DNA or RNA); HIV-1, other region (eg, integrase, fusion)
<b>CYTOPA</b>	THOLOGY
88104	Cytopathology, fluids, washings or brushings, except cervical or vaginal; smears with interpretation
88106 88108	simple filter method with interpretation Cytopathology, concentration technique, smears and interpretation (e.g., Saccomanno technique)
88112	Cytopathology, selective cellular enhancement technique with interpretation (e.g., liquid based slide preparation method), except cervical or vaginal (Do not report 88112 with 88108)
88120	Cytopathology, in situ hybridization (eg, FISH), urinary tract specimen with morphometric analysis, 3-5 molecular probes, each specimen; manual
88121 88141	using computer-assisted technology Cytopathology, cervical or vaginal (any reporting system); requiring interpretation by physician
	(List separately in addition to code for technical service)
88142	Cytopathology, cervical or vaginal (any reporting system), collected in preservative fluid, automated thin layer preparation; manual screening under physician supervision
88143	with manual screening and rescreening under physician supervision
88147	Cytopathology smears, cervical or vaginal; screening by automated system under physician supervision
88148	screening by automated system with manual re-screening under physician supervision
88150	Cytopathology, slides, cervical or vaginal; manual screening under physician supervision
88153	with manual screening and rescreening under physician supervision
88160	Cytopathology, smears, any other source (specify); screening and interpretation
88161	preparation, screening and interpretation
88162 88164	extended study involving over 5 slides and/or multiple stains Cytopathology, slides, cervical or vaginal (the Bethesda System); manual screening under physician supervision
88165	with manual screening and rescreening under physician supervision

CODE	DESCRIPTION
88173 88174	Cytopathology, evaluation of fine needle aspirate; interpretation and report Cytopathology, cervical or vaginal (any reporting system), collected in preservative fluid, automated thin layer preparation; screening by automated system, under physician supervision
88175	with screening by automated system and manual rescreening or review under physician supervision
	(See Rule 22 for instrumented PAP screening definitions)
88184	Flow cytometry, cell surface, cytoplasmic, or nuclear marker, technical component only; first marker
88185	each additional marker (List separately in addition to code for first marker)
88187 88188 88189	Flow cytometry, interpretation; 2 to 8 markers 9 to 15 markers 16 or more markers

## **CYTOGENETIC STUDIES**

Cytogenetic studies procedure codes 88245, 88267 and 88269 must be billed in combination with procedure code 88280 to report a 2-karyotype chromosome analysis as described in the quality control standards for cytogenetic licensure.

88230 88233 88235	Tissue culture for non-neoplastic disorders; lymphocyte skin or other solid tissue biopsy amniotic fluid or chorionic villus cells
88237	Tissue culture for neoplastic disorders; bone marrow, blood cells
88239	solid tumor
88245	Chromosome analysis for breakage syndromes; baseline Sister Chromatid Exchange (SCE), 20-25 cells
88248	baseline breakage, score 50-100 cells, count 20 cells, 2 karyotypes (e.g., for ataxia telangiectasia, Fanconi anemia, fragile X)
88249	score 100 cells, clastogen stress (e.g., diepoxybutane, mitomycin C, ionizing radiation, UV radiation)
88262	Chromosome analysis; count 15-20 cells, 2 karyotypes, with banding
88263	count 45 cells for mosaicism, 2 karyotypes, with banding
88267	Chromosome analysis, amniotic fluid or chorionic villus, count 15 cells, 1 karyotype, with banding
88269	Chromosome analysis, in situ for amniotic fluid cells, count cells from 6-12 colonies, 1 karyotype, with banding
88271	Molecular cytogenetics; DNA probe, each (e.g. FISH)
88272	chromosomal in situ hybridization, analyze 3-5 cells (e.g. for derivatives and markers)
88273	chromosomal in situ hybridization, analyze 10-30 cells (e.g. for microdeletions)

CODE	DESCRIPTION
88274 88275 88280	interphase in situ hybridization, analyze 25-99 cells interphase in situ hybridization, analyze 100-300 cells Chromosome analysis; additional karyotypes, each study (Use in addition to code 88267, 88269)
88285	additional cells counted, each study (Use in addition to code 88269)
88291	Cytogenetics and molecular cytogenetics, interpretation and report

## SURGICAL PATHOLOGY

Surgical pathology procedure codes are reimbursable per specimen. A specimen is defined as tissue or tissues that is (are) submitted for individual and separate attention, requiring individual examination and pathologic diagnosis. Any unlisted specimen should be assigned to the code which most closely reflects the work involved when compared to other specimens assigned to that code.

### 88302 LEVEL II - Surgical pathology, gross and microscopic examination

Appendix, Incidental
Fallopian Tube, Sterilization
Fingers/Toes, Amputation,
Traumatic

Foreskin, Newborn Hernia Sac, Any Location Hydrocele Sac Nerve Skin, Plastic Repair Sympathetic Ganglion Testis, Castration Vaginal Mucosa, Incidental Vas Deferens, Sterilization

## 88304 LEVEL III - Surgical pathology, gross and microscopic examination

Abortion, Induced	Diverticulum -	Neuroma-
Abscess	Esophagus/Small Intestine	Morton's/Traumatic
Aneurysm - Arterial/Ventricular	Dupuytren's Contracture	Pilonidal Cyst/Sinus
Anus, Tag	Tissue	Polyps, Inflammatory -
Appendix, Other than Incidental	Femoral Head,	Nasal/Sinusoidal
Artery, Atheromatous Plaque	Other than Fracture	Skin - Cyst/Tag/Debridement
Bartholin's Gland Cyst	Fissure/Fistula	Soft Tissue, Debridement
Bone Fragment(s),	Foreskin, Other than Newborn	Soft Tissue, Lipoma
Other than	Gallbladder	Spermatocele
Pathologic Fracture	Ganglion Cyst	Tendon/Tendon Sheath
Bursa/Synovial Cyst	Hematoma	Testicular Appendage
Carpal Tunnel Tissue	Hemorrhoids	Thrombus or Embolus
Cartilage, Shavings	Hydatid of Morgagni	Tonsil and/or Adenoids
Cholesteatoma	Intervertebral Disc	Varicocele
Colon, Colostomy Stoma	Joint, Loose Body	Vas Deferens, Other than
Conjunctiva - Biopsy/Pterygium	Meniscus	Sterilization
Cornea	Mucocele, Salivary	Vein, Varicosity
00005 15/51 11/ 0 '	1 (1 )	

### 88305 LEVEL IV - Surgical pathology, gross and microscopic examination

Abortion - Spontaneous/	Heart Valve	Polyp, Stomach/Small Intestine
Missed	Joint, Resection	Prostate, Needle Biopsy
Artery, Biopsy	Kidney, Biopsy	Prostate, TUR
Bone Marrow, Biopsy	Larynx, Biopsy	Salivary Gland, Biopsy
Bone, Exostosis	Leiomyoma (s), Uterine	Sinus, Paranasal Biopsy
Brain/Meninges, Other than	Myomectomy without Uterus	Skin, Other than Cyst/Tag/
For Tumor Resection	Lip, Biopsy/Wedge Resection	Debridement/Plastic Repair
Breast, Biopsy, Not Requiring	Lung, Transbronchial Biopsy	Small Intestine, Biopsy
Microscopic Evaluation of	Lymph Node, Biopsy	Soft Tissue, Other than
Surgical Margins	Muscle, Biopsy	Tumor/Mass/Lipoma/Debridement

Breast, Reduction Mammoplasty Bronchus, Biopsy Cell Block, Any Source Cervix, Biopsy Colon, Biopsy Duodenum, Biopsy Endocervix, Curettings/Biopsy Endometrium Curettings/Biopsy Esophagus, Biopsy Extremity, Amputation, Traumatic Fallopian Tube, Biopsy Fallopian Tube, **Ectopic Pregnancy** Femoral Head, Fracture

Finger/Toes, Amputation,

Gingiva/Oral Mucosa, Biopsy

Non-traumatic

#### DESCRIPTION

Nasal Mucosa, Biopsy Nasopharynx/Oropharynx, Biopsy Nerve, Biopsy Odontogenic/Dental Cyst Omentum, Biopsy Ovary with or without Tube, Non-neoplastic Ovary, Biopsy/ Wedge Resection Parathyroid Gland Peritoneum, Biopsy Pituitary Tumor Placenta, Other than **Third Trimester** Pleura/Pericardium-Biopsy/Tissue Polyp, Cervical/Endometrial

Stomach, Biopsy Synovium Testis, Other than Tumor/ Biopsy/Castration Thyroglossal Duct/Brachial Cleft Cyst Tongue, Biopsy Tonsil, Biopsy Trachea, Biopsy Ureter, Biopsy Urethra, Biopsy Urinary Bladder, Biopsy Uterus, with or without Tubes & Ovaries, for Prolapse Vagina, Biopsy Vulva/Labia, Biopsy

Spleen

## 88307 LEVEL V - Surgical pathology, gross and microscopic examination

Polyp, Colorectal

Adrenal, Resection
Bone - Biopsy/Curettings
Bone Fragment(s),
Pathologic Fracture
Brain, Biopsy
Brain/Meninges,
Tumor Resection
Breast, Excision of Lesion,
Requiring Microscopic
Evaluation of Surgical
Margins
Breast, Mastectomy -

Preast, Mastectomy Partial/Simple
Cervix, Conization
Colon, Segmental Resection,
Other than for Tumor
Extremity, Amputation,
Non-traumatic
Eye, Enucleation

Kidney, Partial/Total Nephrectomy Larynx, Partial/Total Resection Liver, Biopsy -Needle/Wedge Liver. Partial Resection Lung, Wedge Biopsy Lymph Nodes, Regional Resection Mediastinum, Mass Myocardium, Biopsy Odontogenic Tumor Ovary with or without Tube, Neoplastic Pancreas, Biopsy Placenta, Third Trimester Prostate, Except Radical

Resection

Salivary Gland Sentinel Lymph Node Small Intestine, Resection, Other than for Tumor Soft Tissue Mass (except Lipoma) - Biopsy/Simple Excision Stomach - Subtotal/Total Resection, Other than for Tumor Testis, Biopsy Thymus, Tumor Thyroid, Total/Lobe Ureter, Resection Urinary Bladder, TUR Uterus, with or without Tubes and Ovaries, Other than Neoplastic/Prolapse

### **DESCRIPTION**

### 88309 LEVEL VI - Surgical pathology, gross and microscopic examination

Bone Resection
Breast, Mastectomy - with
Regional Lymph Nodes
Colon, Segmental Resection
for Tumor
Colon, Total Resection
Esophagus, Partial/
Total Resection
Extremity, Disarticulation
Fetus, with Dissection
Larynx, Partial/Total

Resection - with Regional

Lung - Total/Lobe/ Segment Resection Pancreas - Total/Subtotal Resection Prostate, Radical Resection Small Intestine, Resection for Tumor Soft Tissue Tumor, Extensive Resection Stomach - Subtotal/Total Resection, Tumor

..Lymph Nodes

Testis, Tumor
Tongue/Tonsil Resection for Tumor
Urinary Bladder, Partial/
Total Resection
Uterus, with or without
Tubes & Ovaries,
Neoplastic
Vulva - Total/
Subtotal Resection

88312 Special stain including interpretation and report; Group I for microorganisms (eg, acid fast, methenamine silver)

(Report one unit of 88312 for each special stain, on each surgical pathology block, cytologic specimen, or hematologic smear)

Group II, all other (eg, iron, trichrome), except stain for microorganisms, stains for enzyme constituents, or immunocytochemistry and immunohistochemistry

(Report one unit of 88313 for each special stain, on each surgical pathology block, cytologic specimen, or hematologic smear)

88319 Group III, for enzyme constituents

(For each stain on each surgical pathology block, cytologic specimen, or hematologic smear, use one unit of 88319)

88342 Immunohistochemistry (including tissue immunoperoxidase), each antibody

(For immunophenotyping, see Rule 18)

88346 Immunofluorescent study, each antibody; direct method

88347 indirect method

88360 Morphometric analysis, tumor immunohistochemistry (e.g., Her-2/Neu, estrogen receptor/progesterone receptor), quantitative or semiquantitative, each antibody; manual

using computer assisted technology (computer generated)

(Do not report 88360 or 88361 with 88342 unless each procedure is for a different antibody)

(When semi-thin plastic-embedded sections are performed in conjunction with morphometric analysis, only the morphometric analysis should be reported; if performed as an independent procedure, see codes 88302-88309 for surgical pathology)

## **OTHER PROCEDURES**

89050 Cell count, miscellaneous body fluids (e.g., cerebrospinal fluid, joint fluid), except blood;

89051 with differential count

89055 Leukocyte assessment, fecal, qualitative or semiquantitative

89060 Crystal identification by light microscopy with or without polarizing lens

## **Laboratory Procedure Codes**

CODE	DESCRIPTION
89190 89230 89321 91065 P9604	analysis, tissue or any body fluid (except urine) Nasal smear for eosinophils Sweat collection by iontophoresis (includes analysis) Semen analysis; sperm presence and motility of sperm, if performed Breath hydrogen test (e.g., for detection of lactase deficiency, fructose intolerance, bacterial overgrowth, or oro-cecal gastrointestinal transit) Travel allowance one way in connection with medically necessary laboratory specimen collection drawn from home bound or nursing home bound patient;
	prorated trip charge (Limited to home bound phlebotomy; see Rule 23)
S3840	DNA analysis for germline mutations of the RET proto-oncogene for susceptibility to multiple endocrine neoplasia type 2
S3842 S3844	Genetic testing for Von Hippel-Lindau disease DNA analysis of the connexin 26 gene (GJB2) for susceptibility to congenital, profound deafness
S3846	Genetic testing for hemoglobin E beta-thalassemia
S3849	Genetic testing for Niemann-Pick disease
S3850 S3852	Genetic testing for sickle cell anemia
S3853	DNA analysis for APOE epilson 4 allele for susceptibility to Alzheimer's disease Genetic testing for myotonic muscular dystrophy
S3861	Genetic testing, sodium channel, voltage-gated, type V, alpha subunit (SCN5A) and variants for suspected Brugada Syndrome
S3865 S3866	Comprehensive gene sequence analysis for hypertrophic cardiomyopathy Genetic analysis for a specific gene mutation for hypertrophic cardiomyopathy (HCM) in an individual with a known HCM mutation in the family